Related by context. All words. (Click for frequent words.) 83 AIR CF2 78 AIR CF3 70 multicenter multinational 70 Phase IIIb 69 blinded randomized placebo controlled 69 REVIVE Diabetes 69 INSPIRE Trial Phase III 69 GSK# [001] 68 placebo controlled Phase III 68 Phase IIIb study 68 phase IIIb 68 sorafenib tablets 68 PEGINTRON TM 68 oral rivaroxaban 68 Phase Ib clinical 68 Phase 1b trial 67 phase IIa 67 relapsed MM 67 CIMZIA TM certolizumab pegol 67 multicenter Phase 67 placebo controlled clinical 67 Phase #/#a 67 phase Ib 67 acyclovir Lauriad R 67 Aryplase 67 evaluating tivozanib 67 phase IIb clinical 67 randomized Phase IIb 66 phase IIa clinical 66 multicenter Phase III 66 lenalidomide Revlimid R 66 dasatinib Sprycel ® 66 dextromethorphan quinidine 66 CHAMPION PCI 66 multicenter placebo controlled 66 MAGE A3 ASCI 66 pharmacokinetic PK study 66 ADVANCE PD 66 phase IIb study 66 erlotinib Tarceva ® 66 CLARITY TIMI 66 TMC# C# 66 virus HCV protease inhibitor 66 ascending dose 66 CIMZIA TM 66 cisplatin gemcitabine 66 NSABP B 66 dose escalation phase 66 refractory chronic lymphocytic 65 dose escalation study 65 multicenter Phase II 65 interferon gamma 1b 65 receptor tyrosine kinase inhibitor 65 dyskinesia PD LID 65 blinded placebo controlled 65 Aflibercept 65 EQUIP OB 65 Carotid Revascularization Endarterectomy vs. 65 BRIM2 65 Phase Ib clinical trials 65 Tanespimycin 65 prospective randomized multicenter 65 relapsing multiple sclerosis 65 relapsed refractory multiple myeloma 65 Traficet EN 65 ORENCIA ® 65 Xelox 65 Phase 2b Clinical Trial 65 PEGylated interferon beta 1a 65 double blinded randomized 65 GW# [003] 65 visilizumab 65 Phase IIb Trial 65 Navelbine ® 65 prospective observational 65 de novo kidney transplant 65 APTIVUS r 65 active comparator 65 thorough QT 65 EDEMA3 65 lexidronam injection 65 Zenvia Phase III 65 randomized controlled multicenter 65 RSD# oral 65 SPRYCEL ® 65 Phase 1b clinical 65 Folfox 65 Zenvia ™ 65 FUSILEV enhances 65 Phase IIIb clinical 65 Hsp# Inhibitor 65 budesonide pMDI 65 placebo controlled Phase 65 stage IIIb IV 65 Phase 2a trial 65 vapreotide acetate 65 Phase 1b 65 dose dose escalation 64 Phase 1b clinical trials 64 Cimzia TM 64 delivers fluocinolone acetonide FA 64 multicenter randomized placebo controlled 64 Phase 2b study 64 relapsing remitting MS RRMS 64 serum phosphorous 64 ascending doses 64 administered subcutaneously 64 brand ciclesonide HFA 64 COU AA 64 assessing T DM1 64 Phase IIa trial 64 HCV RESPOND 2 64 RRMS patients 64 ARCALYST ® 64 FOLFOX6 chemotherapy regimen 64 PDX pralatrexate 64 Phase 1a clinical 64 ACTEMRA TM 64 FOLFIRI 64 Raptiva r 64 Phase 2a clinical 64 CYT# potent vascular disrupting 64 PEGASYS ® 64 azilsartan medoxomil 64 Pegasys ® 64 APTIVUS 64 Investigational Treatment 64 GOUT 64 colesevelam HCl 64 CLARITY study 64 recurrent glioblastoma multiforme 64 refractory CLL 64 CAMMS# 64 liposome injection 64 placebo controlled 64 Phase IIa trials 64 dosing cohort 64 Prospective Randomized 64 Cloretazine 64 Phase III multicenter 64 FAME Study 64 forodesine 64 posaconazole 64 TYKERB 64 stage IIIB 64 Ixempra 64 placebo controlled randomized 64 eosinophilic asthma 64 R lenalidomide 64 REVLIMID lenalidomide 64 pegylated interferon alpha 64 placebo controlled clinical trials 64 prospective multicenter 64 ENDEAVOR IV 64 phase IIb trial 64 PREZISTA r 64 plus prednisone 64 Initiated Phase 64 headache nasopharyngitis 64 riociguat 64 MERLIN TIMI 64 docetaxel Taxotere ® 64 DOXIL 64 double blinded placebo 63 nab paclitaxel 63 fosbretabulin 63 mg RDEA# 63 multicenter randomized double 63 prokinetic agent 63 null responder HCV 63 Randomized Double blind 63 multicenter clinical 63 Dacogen injection 63 ZACTIMA 63 nucleotide analogue 63 CTA# Injection 63 sunitinib malate 63 RAPTIVA 63 FOLPI 63 DEB# 63 CIMZIA ™ 63 Aztreonam lysine 63 ribavirin RBV 63 FOLOTYN ® 63 controlled multicenter 63 FASLODEX 63 Temsirolimus 63 ritonavir boosted 63 OPT CHF 63 sorafenib Nexavar 63 8mg/kg 63 acetonide FA 63 KAPIDEX 63 oral ridaforolimus 63 masked placebo controlled 63 randomized Phase III 63 treatment naive genotype 63 GATTEX ™ 63 galiximab 63 randomized multicenter 63 viral kinetic 63 Pivotal Clinical Trial 63 severe hypercholesterolemia 63 Intervention Effectiveness 63 Zorbtive TM 63 CONQUER OB 63 dose escalation clinical 63 Phase 2a 63 evaluating Xcytrin 63 randomized multicenter trial 63 Combination REOLYSIN R 63 BoNTA 63 AGILECT R 63 metastatic hormone refractory 63 Elotuzumab 63 cediranib 63 By JENNIFER LEARN 63 budesonide foam 63 BCG refractory carcinoma 63 Pivotal Phase III 63 placebo controlled studies 63 5 FU leucovorin 63 adalimumab Humira 63 RECORD1 63 pegylated interferon alfa 2b 63 COMFORT II 63 number NCT# ClinicalTrials.gov 63 HCV SPRINT 63 Tarceva TM 63 Pivotal Trial 63 rFVIIa 63 Perforomist ™ Inhalation Solution 63 prospective multicenter randomized 63 AVASTIN 63 metastatic malignant 63 II Clinical Trial 63 ALN HPN 63 mg administered orally 63 Telik logo TELINTRA 63 elotuzumab 63 confirmatory Phase III 63 pertuzumab 63 PANVAC VF 63 KRN# 63 TRANSDUR ™ 63 acute PAO 63 PRECiSE 63 cell lymphoma CTCL 63 dose escalation Phase 63 alfa 2a 63 Meets Primary Endpoint 63 IMPACT DCM 63 LUMINATE 63 AVOREN 63 Phase III randomized 63 myelodysplastic myeloproliferative diseases 63 Phase #b/#a 63 GEM OS2 63 R# #mg BID 63 Ozarelix 63 trastuzumab Herceptin ® 63 desvenlafaxine succinate 63 IV bolus 63 standard chemotherapy regimen 63 Phase Ib 63 Quinamed 63 GetGoal Phase III 63 postmenopausal osteoporotic women 63 PNP inhibitor 63 primary hypercholesterolemia 63 mitoxantrone plus 63 GAMMAGARD 63 randomized #:#:# 63 Ranolazine 63 #mg BID [001] 63 ARIKACE 63 Phase III placebo controlled 63 dose escalation trial 63 Phase 2b Trial 63 Newly Diagnosed Multiple Myeloma 63 #mg ATC 63 Pivotal Study 63 BRIM3 63 recurrent NSCLC 63 CANCIDAS 63 Myocardial Infarction Study 63 pseudobulbar affect PBA 63 inhalations twice 63 Pharmacokinetic Study 63 Gemzar ® 63 plus prednisone prednisolone 62 multicentre randomized 62 Phase IIb clinical trials 62 refractory multiple myeloma 62 fluvastatin 62 Study Evaluating 62 BARACLUDE ® 62 Completes Patient Enrollment 62 nonrandomized 62 TYGACIL 62 nilotinib Tasigna ® 62 APEX PD 62 Xeloda ® 62 ZOLINZA 62 NATRECOR ® 62 CIMZIA R 62 pomalidomide 62 Phase Ib study 62 relapsed myeloma 62 Inhalation Aerosol 62 #mg QD [002] 62 efalizumab 62 randomized controlled Phase 62 Pafuramidine 62 melphalan prednisone 62 Non Alcoholic Steatohepatitis 62 Double Blind Placebo 62 pegylated alpha interferon 62 antibody MAb 62 anthracycline taxane 62 R adefovir dipivoxil 62 efavirenz EFV 62 bepotastine besilate nasal spray 62 salmeterol fluticasone 62 orally inhaled 62 DAPT 62 Blinatumomab 62 prospective randomized controlled 62 Phase III Clinical Trial 62 Teriflunomide 62 ISTODAX ® 62 lintuzumab SGN 62 comparator arm 62 atazanavir sulfate 62 evaluating mipomersen 62 miconazole Lauriad ® 62 candesartan cilexetil 62 mg QD 62 AIR2 Trial 62 Torisel 62 Inhalation Solution 62 NDA Submission 62 methylnaltrexone bromide 62 dacarbazine DTIC 62 arsenic trioxide injection 62 Phase IIb Clinical Trial 62 pegylated interferon alfa 2a 62 CALGB # [002] 62 oxymorphone ER 62 prospective nonrandomized 62 Phase Ia 62 STRIDE PD 62 docetaxel Taxotere R 62 irbesartan 62 Pivotal Phase 62 intravesical infusion therapy 62 Onrigin 62 pregabalin Lyrica 62 INFERGEN 62 Fibrillex TM 62 Diabetic Macular Edema 62 pivotal bioequivalence 62 Sapacitabine 62 Hypersensitivity reactions 62 Bezielle 62 nevirapine Viramune 62 anti muscarinic 62 Clinical Antipsychotic Trials 62 Diabetic Macular Edema DME 62 Oral Fingolimod 62 LEVAQUIN ® 62 recurrent metastatic 62 neratinib 62 Omacetaxine 62 Phase IIa 62 mg BID 62 CALGB 62 dose cohort 62 thalidomide Thalomid 62 q8h 62 doxorubicin cyclophosphamide 62 NOXAFIL Oral Suspension 62 phase Ib clinical 62 rilonacept 62 CINQUIL 62 Perforomist Inhalation Solution 62 mertansine 62 Demonstrate Significant 62 Phase Ib IIa 62 VELCADE melphalan 62 basal bolus regimen 62 hyperphenylalaninemia HPA due 62 symptomatic BPH 62 blind multicenter 62 hormone refractory metastatic prostate 62 Controlled Trial 62 trastuzumab Herceptin R 62 mcg BID 62 fenofibric acid 62 LIALDA 62 somatostatin analog 62 TO AVOID PREGNANCY WHILE 62 dosing cohorts 62 Triapine 62 Pegloticase 62 Prostate AdenoCarcinoma Treatment 62 certolizumab 62 opioid naive 62 MGd 62 alvespimycin 62 Investigational Oral 62 beta 1a 62 multicenter randomized 62 HCV NS5B polymerase 62 multicenter prospective 62 Acute Ischemic Stroke 62 icatibant 62 oral prodrug 62 serotonin norepinephrine reuptake inhibitor 62 randomized blinded 62 opioid induced bowel dysfunction 62 Ophena TM 62 weekly subcutaneous injections 62 etanercept Enbrel 62 Unstable Angina 62 malignant mesothelioma Alfacell 62 novel orally inhaled 62 REVLIMID ® 62 phase IIb 62 MoxDuo TM IR 62 Randomized Phase 62 huC# DM4 62 DASISION 62 stable angina pectoris 62 Velcade bortezomib 62 albinterferon alfa 2b 62 Phase #b/#a clinical 62 Demonstrates Sustained 62 EINSTEIN DVT 62 Mycophenolate Mofetil 62 post herpetic neuralgia PHN 62 4mg/kg 62 metformin HCl 62 Myelodysplastic Syndrome MDS 62 #mg q8h 62 CAPRIE 62 vismodegib 62 multicenter randomized controlled 62 evaluating T DM1 61 TELINTRA 61 Raptiva ® 61 6R BH4 61 multicentre randomized double 61 dexamethasone Decadron 61 Metastatic Prostate Cancer 61 #I TM# 61 Fludara 61 Naive Patients 61 EXPLORE Xa 61 Granted Orphan Drug 61 CTAP# Capsules 61 Pemetrexed 61 unique alkylating agent 61 TDF FTC 61 mcg QD 61 novel VDA molecule 61 catheter occlusion 61 irinotecan doxorubicin oxaliplatin paclitaxel 61 phase 2a 61 Neovascular AMD 61 mapatumumab 61 carboplatin paclitaxel 61 temsirolimus 61 ergot derivatives 61 Certolizumab 61 PEG SN# 61 antiretroviral naive 61 THAT ARE DIFFICULT TO 61 Hypertensive adverse reactions 61 Carfilzomib 61 axitinib 61 intradermal injections 61 ELADUR ™ 61 IMiDs ® compound 61 ALN VSP Phase 61 RG# [001] 61 pioglitazone HCl 61 BENICAR HCT 61 registrational Phase 61 Dapagliflozin 61 VICTOR E1 61 Randomized Phase II 61 Enzastaurin 61 vaccinated PNH patients 61 Hepatotoxicity 61 Phase 2b trial 61 BR.# 61 TAXUS ATLAS 61 rosuvastatin #mg 61 ORENCIA R 61 GEM OS1 61 Eculizumab 61 Mg Uk 61 panitumumab Vectibix 61 dirucotide MBP# 61 mGluR5 negative 61 sertraline Zoloft 61 Phase Ib II 61 oral dual endothelin 61 oropharyngeal candidiasis OPC 61 EmbraceAC 61 prospective randomized placebo 61 Systemic Sclerosis 61 sunitinib Sutent 61 multicenter phase 61 aripiprazole Abilify 61 ruboxistaurin 61 Engerix B 61 JAK inhibitor 61 unresectable Stage III 61 diarrhea predominant irritable 61 R Saizen R 61 ARIXTRA 61 receiving INTRON 61 Glatiramer Acetate 61 ABSORB trial 61 pediatric Crohn disease 61 TLK# 61 CAELYX 61 Tracleer R 61 balsalazide tablet 61 Dalbavancin 61 adult chronic ITP 61 randomized placebo controlled 61 Randomized Clinical Trial 61 peg IFN 61 antiretroviral naïve 61 ALVESCO 61 APTIVUS ritonavir 61 brivaracetam 61 ocular formulation 61 Long Term Efficacy 61 ARCOXIA 61 #mg/day [001] 61 Xibrom TM 61 pan histone deacetylase 61 receiving prophylactic anticoagulation 61 gadobutrol 61 mcg albinterferon alfa 2b 61 recurrent metastatic ovarian cancer 61 RELOVAIR ™ 61 oral FTY# 61 dependent kinase inhibitor 61 COPAXONE R 61 Pooled Analysis 61 ascending dose study 61 Desvenlafaxine Succinate 61 SCH # 61 metastatic renal cell carcinoma 61 ATACAND 61 thiazolidinedione TZD 61 telaprevir dosing 61 DAVANAT 61 randomized crossover 61 q#h 61 See CLINICAL PHARMACOLOGY 61 EDEMA3 trial 61 Phase #/#a trial 61 CAPACITY trials 61 albiglutide 61 oral chemotherapeutic agent 61 humanized therapeutic 61 PROMUS R 61 salmeterol inhalation powder 61 Sprycel dasatinib 61 dalteparin 61 ganetespib 61 Placebo Controlled Trial 61 PROPEL trial 61 CB2 selective receptor agonist 61 selective androgen receptor modulator 61 VIVITROL ® 61 Daclizumab 61 telaprevir dosed 61 HER2 positive metastatic breast 61 superficial bladder cancer 61 SNT MC# 61 Relapsed Multiple Myeloma 61 trastuzumab DM1 T DM1 61 NATRECOR R 61 RANK Ligand inhibitor 61 Pharmacokinetic parameters 61 5 fluorouracil leucovorin 61 TORISEL 61 IL# PE#QQR 61 risperidone Risperdal 61 Denufosol 61 Tezampanel 61 Metabolic Efficiency 61 Pegylated Liposomal Doxorubicin 61 ritonavir boosted atazanavir 61 occlusion PAO 61 evaluating carfilzomib 61 Peginterferon 61 Rilonacept 61 peginterferon alfa 2b 61 Amrubicin 61 metastatic HRPC 61 COSIRA trial 61 Kamada AAT 61 receiving VELCADE 61 Intravitreal 61 Initiates Enrollment 61 AEGR 61 Cannabinor 61 mg TID 61 label dose titration 61 oxycodone CR 61 Edge STudy 61 BARACLUDE R 61 dihydroergotamine DHE 61 placebo controlled trials 61 Albuferon TM 61 retrospective observational study 61 prucalopride 61 PROMACTA 61 COPEGUS ribavirin 61 5 Fluorouracil 61 citalopram hydrobromide 61 Serostim ® 61 LibiGel Phase III 61 venlafaxine ER 61 ISENTRESS 61 Dual Opioid 61 aspirin clopidogrel 61 phase III isavuconazole 61 GSK# [002] 61 Sirolimus eluting Coronary Stent 61 Parkinson disease levodopa induced 61 Clinical Trial Evaluating 61 Capesaris 61 estramustine 61 EURIDIS 61 multicentre 61 alvimopan 61 Renal Cell Carcinoma RCC 61 LANTUS ® 61 SinuNase TM 61 alefacept 61 epoetin alpha 61 randomized controlled clinical trials 61 peginterferon alfa 2a Pegasys 61 bone marrow reticulin deposition 61 Phase 2a Trial 61 Endovascular Valve Edge 61 PF # [002] 61 Paraplatin ® 61 evaluating Actimmune 61 metastatic castration resistant 61 AVADO 61 BAY #-# 61 blind randomized multicenter 61 diabetic neuropathic pain 61 Advanced Renal Cell 61 Cimzia certolizumab pegol 61 FIRMAGON 61 herpetic keratitis 61 adenosine injection 61 5mg/kg 61 CRLX# 61 ug dose 61 morphometric vertebral fractures 60 FDA APPROVES 60 worsening thrombocytopenia 60 heFH 60 Onrigin TM 60 Adjuvant Treatment 60 R sorafenib tablets 60 pharmacokinetic PK 60 Betaferon ® 60 baminercept 60 Platinol ® 60 unstable angina UA 60 prospective multicentre 60 pharmacokinetics PK 60 Severe Asthma 60 BENICAR 60 alpha 2a 60 Hepsera adefovir dipivoxil 60 papillary renal cell carcinoma 60 BCIRG 60 Mylotarg 60 HuMax EGFr 60 psoriatic arthritis PsA 60 Phase 1a 60 Phase #b/#a trial 60 Pharmacokinetics PK 60 daily Infergen 60 blind randomized placebo 60 rFSH 60 Phase IIB 60 YONDELIS 60 Elagolix 60 TG MV 60 HMG CoA reductase inhibitors 60 SPIRIT FIRST 60 Epoetin alfa 60 paclitaxel Taxol R 60 Irinotecan 60 ongoing Phase 1b 60 metastatic GIST 60 Central Retinal Vein 60 CERVARIX 60 crizotinib PF # 60 ALN TTR 60 BZA CE 60 Randomized Evaluation 60 compound INCB# 60 teriflunomide 60 AMEVIVE 60 PERSEUS clinical program 60 Acetate Rectal Suppositories 60 ERBITUX cetuximab 60 PD LID 60 #.#mg/dL 60 3TC lamivudine Epivir 60 ® pioglitazone HCl 60 specified secondary endpoints 60 leukemia CLL 60 cancer neuroendocrine tumor 60 decompensated liver disease 60 mycophenolate mofetil 60 intravenous RSD# 60 Hepatocellular Carcinoma HCC 60 Augment TM 60 urinary N telopeptide 60 PRN FDA Approves 60 Phase IIa clinical 60 VADT 60 multiple ascending dose 60 HCD# [002] 60 subcutaneously administered 60 Ovitrelle R Serostim 60 labial herpes 60 Xanafide 60 paclitaxel poliglumex 60 ANCHOR trial 60 lacosamide 60 Adalimumab 60 Phase III metastatic melanoma 60 CLL8 60 aflibercept VEGF Trap 60 Betaferon R 60 leukemia AML 60 patients undergoing percutaneous 60 Clolar ® 60 oral vancomycin 60 peginterferon alfa 2a 60 randomized multicenter Phase III 60 Primary endpoints 60 Methylnaltrexone 60 First Patient Enrolled 60 multi kinase inhibitor 60 cetuximab Erbitux R 60 inhaled corticosteroid ICS 60 familial amyloidotic polyneuropathy FAP 60 PROVENGE sipuleucel T 60 arterial thromboembolic 60 ADVANCE ILLUMINATE 60 Proellex TM 60 cannabinor 60 Dose Ranging Study 60 HQK 60 Complicated Skin 60 FOLFOX4 60 venlafaxine XR 60 bupropion SR 60 Severe Sepsis 60 randomized #:# 60 pegylated liposomal doxorubicin 60 QLT# 60 Nebulized 60 tgAAC# 60 NO# [002] 60 orally administered inhibitor 60 Phase 2b clinical 60 bortezomib Velcade R 60 lenalidomide dexamethasone 60 Entereg R 60 Trial Evaluating 60 Taxotere ® 60 multicenter randomized clinical 60 Plicera 60 treatment naïve genotype 60 midstage clinical 60 Serevent salmeterol 60 VICTOR E3 60 mITT population 60 nucleoside naive 60 biologic DMARD 60 Forodesine HCl 60 XOMA 3AB 60 sapacitabine CYC# 60 endoscopic remission 60 Zemplar Capsules 60 EVEREST II 60 Adjunctive Therapy 60 histone deacetylase HDAC inhibitor 60 controlled dose escalation 60 Iluvien ® 60 CATIE AD 60 Omacetaxine mepesuccinate 60 docetaxel chemotherapy 60 evaluating satraplatin 60 PHX# 60 TRA 2P 60 Raloxifene Evaluation MORE 60 develop HBV reactivation 60 NP2 Enkephalin 60 Advanced Melanoma 60 Dasatinib 60 Phase III Pivotal 60 letrozole Femara 60 IBS C 60 INCB# [001] 60 RE LY 60 ceftazidime 60 Phase Ib Clinical Trial 60 Platinol ® cisplatin 60 ® lenalidomide 60 2 methoxyestradiol 60 unfractionated heparin UFH 60 non nucleoside inhibitor 60 Glufosfamide 60 Raptiva R 60 infliximab monotherapy 60 RoACTEMRA 60 Fx #A 60 palifermin 60 sorafenib Nexavar ® 60 #mg QD [001] 60 Screening Trial 60 Phase IIb trials 60 European Sepsis Trial 60 Doxil ® 60 plus Copegus R 60 CR# vcMMAE 60 single ascending dose 60 Phase III Trial 60 metastatic colorectal 60 TRANSFORMS 60 Targretin capsules 60 divalproex sodium 60 long acting beta2 60 chemotherapy FOLFOX 60 maximally tolerated dose 60 abacavir lamivudine 60 HFA MDI 60 Medoxomil 60 bendamustine 60 LEXIVA r 60 PEGylated anti 60 Alkeran 60 Arranon 60 Randomized Controlled 60 prednisone prednisolone plus 60 clevidipine 60 Romiplostim 60 Aeroquin 60 SYNERGY Stent 60 ONTARGET 60 intermittent dosing 60 ULORIC 60 AAG geldanamycin analog 60 vandetanib 60 gefitinib Iressa 60 mRCC 60 Pegasys plus Copegus 60 Medidur TM FA 60 HGS# 60 Keppra XR 60 dose regimens 60 TELCYTA 60 cyclophosphamide methotrexate 60 pivotal Phase III 60 metastatic CRPC 60 ROCKET AF 60 DU #b 60 paroxetine Paxil 60 Investigational Drug 60 Bosutinib 60 refractory NSCLC 60 zonisamide SR 60 JAK2 Inhibitor 60 flutamide 60 MEK Inhibitor 60 Actimmune ® 60 endothelin receptor antagonists 60 ibandronate 60 immunomodulatory therapy 60 novel oral anticoagulant 60 rasagiline tablets 60 tipranavir r 60 landmark ATHENA 60 analgesic efficacy 60 Pulmonary Arterial Hypertension 60 undergoing elective percutaneous 60 Urocortin 2 60 PROMUS Element Stent 60 TRANSDUR ® 60 PEG IFN 60 XIENCE V PROMUS Stent 60 LymphoStat B belimumab 60 Patients Receiving 60 metastatic colorectal carcinoma 60 ACTIVE W 60 sNDA submission 60 Phase III confirmatory 60 Cariprazine 60 MEND CABG 60 hemodynamically significant 60 metformin sulfonylurea 60 memantine HCl 60 Tolvaptan 60 Saxagliptin 60 Prostate Lung Colorectal 60 constipation OIC 60 #mg BID [003] 60 BOLDER II 60 Altera Nebulizer System 60 trials RCTs 60 Phase 2b Study 60 rALLy clinical trial 60 Presents Positive 60 Panzem R 60 MIRAPEX 60 Navelbine 60 Phase 2a clinical trials 60 metastatic CRC 60 PERSEUS 60 NOX E# 60 PRESEPT 60 adriamycin 60 bevirimat Study 60 transthyretin mediated amyloidosis ATTR 60 mg q#h 60 Mg Usa 60 Hormone Refractory Prostate Cancer 60 GERD migraine headaches 60 Phase III randomized controlled 60 LymphoStat B TM 60 Multicenter 60 oxycodone IR 60 Single Dose 60 sunitinib Sutent ® 60 REGN# 59 adalimumab 59 MEVACOR 59 included exfoliative dermatitis 59 SEROQUEL R 59 Tipranavir 59 liposomal formulation 59 SAR# [004] 59 dual endothelin receptor antagonist 59 tasocitinib 59 CHARISMA trial 59 Recurrent Glioblastoma 59 combines bupropion 59 randomized controlled clinical 59 Acute Coronary Syndromes ACS 59 systemic RNAi therapeutic 59 ARCALYST ® rilonacept 59 peripherally acting 59 CYPHER R Sirolimus eluting 59 alpha interferons 59 Nesiritide 59 ALGRX 59 Patients Treated With 59 HORIZONS AMI 59 TACI Ig 59 elective PCI 59 Phase III pivotal 59 lintuzumab 59 topiramate Topamax 59 CCX# B 59 Eluting Stent 59 saline placebo 59 Phase III Psoriasis 59 preclinical efficacy 59 SABCS 59 Randomized Double Blind Placebo 59 5-FU/LV 59 homozygous familial hypercholesterolemia 59 Dacogen decitabine 59 bevacizumab Avastin ® 59 NVA# 59 XL# anticancer compounds 59 PROCHYMAL 59 Peg IFN